


PLASTIC & CHEMICALS 2020

CYC Continuous therapeutics

Cyclo Therapeutics Inc. Rank 75 of 75





PLASTIC & CHEMICALS 2020



Cyclo Therapeutics Inc. Rank 75 of 75

The relative strengths and weaknesses of Cyclo Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cyclo Therapeutics Inc. compared to the market average is the variable Cost of Revenues, increasing the Economic Capital Ratio by 621% points. The greatest weakness of Cyclo Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 1,440% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,480%, being 1,518% points below the market average of 38%.

Input Variable	Value in 1000 USD
Assets, Current	3,958
Assets, Noncurrent	51
Cost of Revenues	0
Intangible Assets	0
Liabilities, Current	3,141
Liabilities, Noncurrent	0
Other Assets	91
Other Compr. Net Income	0
Other Expenses	3,683
Other Liabilities	0
Other Net Income	12
Other Revenues	1,007
Property, Plant and Equipment, Net	14
Selling, General and Administrative Expense	4,869

Output Variable	Value in 1000 USD
Liabilities	3,141
Assets	4,113
Expenses	8,552
Revenues	1,007
Stockholders Equity	972
Net Income	-7,533
Comprehensive Net Income	-7,533
Economic Capital Ratio	-1,480%